Skip to content
value.today

Geno LLC

🇺🇸 Cocoa, Florida, USAPharmaceuticalsFounded 2006
Total raised
$82 M
5 rounds on record
Latest round
$27 M
Dec 2021
First round on record
Sep 2009
Today
Private
No later event on record

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Geno LLC
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2021$27 MNo. 5$10 to $50 million

Geno LLC: Raise no. 5, Dec 2021

Investors in this round

5 investors had bought by the notice of Dec 22, 2021: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$27 M of $100 M offered; $72 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brent V. Furse · Executive Officer, Director
  • Roberto V. Cohen · Executive Officer
  • Shasha V. Zou · Executive Officer
  • Daniel Salazar · Director
  • Eric V. Bednarski · Director
  • Thiago V. Tavares · Director
  • Todd Brady · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Brent V. Furse, President & CEO. Source: SEC Form D, newest notice filed Dec 22, 2021. Read the notice at the SEC.

equitySEC
Sep 2017$30 MNo. 4$10 to $50 million

Geno LLC: Raise no. 4, Sep 2017

Investors in this round

31 investors had bought by the notice of Sep 29, 2017: 29 accredited, 2 not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$30 M of $35 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Delaware

People named in the notice

  • Anthony Scott Loumidis · Executive Officer
  • Brent H. Furse · Executive Officer, Director
  • David H. Fine, Ph.D. · Executive Officer, Director
  • Paul Scott Antinori · Executive Officer
  • Tod Scott Shultz · Executive Officer
  • Dan Scott Salazar, Ph.D. · Director
  • T. Scott Johnson, M.D. · Director
  • Theo Scott Melas-Kyriazi · Director
  • Todd Scott Brady · Director
  • Vinzenz Scott Ploerer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Offering is now closed.”

Signed by Paul Antinori, Secretary and General Counsel. Source: SEC Form D, newest notice filed Sep 29, 2017. Read the notice at the SEC.

equitySEC
Sep 2013$15 MNo. 3$10 to $50 million

Geno LLC: Raise no. 3, Sep 2013

Investors in this round

41 investors had bought by the notice of Oct 18, 2013: 41 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $17 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$347,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Limited Liability Company, incorporated in Delaware

People named in the notice

  • Anthony Loumidis · Executive Officer · Chief Financial Officer.
  • David Fine · Executive Officer, Director · Executive Chairman, Chief Scientific Officer and Managing Member of the LLC.
  • Kurt Dasse · Executive Officer, Director · Chief Executive Officer, President and a Managing Member of the LLC.
  • Robert Roscigno · Executive Officer · Executive Vice President.
  • Steven Shulman · Director · Managing Member of the LLC.
  • Theo Melas-Kyriazi · Director · Managing Member of the LLC.

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Please be advised that the Total Amount Sold above also includes securities issued to investor(s) under Regulation S.”
  • On the use of proceeds: “Compensation to executive officers and directors.”

Signed by Anthony Loumidis, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed Oct 18, 2013. Read the notice at the SEC.

equity, optionsSEC
Feb 2011$8 MNo. 2$2 to $10 million

Geno LLC: Raise no. 2, Feb 2011

Investors in this round

21 investors had bought by the notice of Dec 29, 2011: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $11 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Delaware

People named in the notice

  • David Fine · Executive Officer, Director · David Fine is CEO and Managing Member of the LLC.
  • Kurt Dasse · Executive Officer, Director · Kurt Dasse is an Executive Vice President and a Managing Member.
  • Robert Roscigno · Executive Officer · Robert Roscigno is an Executive Vice President.
  • James O'Brien · Director · James O'Brien is a Managing Member of the LLC.
  • Steven Shulman · Director · Steven Shulman is a Managing Member of the LLC.

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David Fine, President. Source: SEC Form D, newest notice filed Dec 29, 2011. Read the notice at the SEC.

equitySEC
Sep 2009$2 MNo. 1$2 to $10 million

Geno LLC: Raise no. 1, Sep 2009

Investors in this round

18 investors had bought by the notice of Sep 14, 2009: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $3 M offered; $1 M still to sell
Smallest investment taken
$2,500
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
not stated
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Delaware

People named in the notice

  • David Fine · Executive Officer · Mr. Fine is also a Manager and Member
  • James O'Brien · Executive Officer · James O'Brien is a Manager
  • Kurt Dasse · Executive Officer · Kurt Dasse is a Manager
  • Steven Shulman · Executive Officer · Steven Shulman is a Manager

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David Fine, President. Source: SEC Form D and 1 amendment, newest notice filed Sep 14, 2009. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Geno LLC chose not to state its revenue in its newest notice of a funding round (Dec 2021).

    SEC Form D · Dec 2021

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Dec 2021

That is all the official record says: Geno LLC has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Geno LLC is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 41 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Geno LLC
NameRoleNamed in
Brent V. FurseExecutive officerDec 2021
Roberto V. CohenExecutive officerDec 2021
Shasha V. ZouExecutive officerDec 2021
Anthony Scott LoumidisExecutive officerSep 2017
Brent H. FurseExecutive officerSep 2017
David H. Fine, Ph.D.Executive officerSep 2017
Paul Scott AntinoriExecutive officerSep 2017
Tod Scott ShultzExecutive officerSep 2017
Anthony LoumidisChief Financial Officer.Oct 2013
David FineExecutive Chairman, Chief Scientific Officer and Managing Member of the LLC.Oct 2013
Kurt DasseChief Executive Officer, President and a Managing Member of the LLC.Oct 2013
Robert RoscignoExecutive Vice President.Oct 2013
James O'BrienJames O'Brien is a ManagerSep 2009
Steven ShulmanSteven Shulman is a ManagerSep 2009
Brent V. FurseDirectorDec 2021
Daniel SalazarDirectorDec 2021
Eric V. BednarskiDirectorDec 2021
Thiago V. TavaresDirectorDec 2021
Todd BradyDirectorDec 2021
Brent H. FurseDirectorSep 2017
Dan Scott Salazar, Ph.D.DirectorSep 2017
David H. Fine, Ph.D.DirectorSep 2017
T. Scott Johnson, M.D.DirectorSep 2017
Theo Scott Melas-KyriaziDirectorSep 2017
Todd Scott BradyDirectorSep 2017
Vinzenz Scott PloererDirectorSep 2017
David FineExecutive Chairman, Chief Scientific Officer and Managing Member of the LLC.Oct 2013
Kurt DasseChief Executive Officer, President and a Managing Member of the LLC.Oct 2013
Steven ShulmanManaging Member of the LLC.Oct 2013
Theo Melas-KyriaziManaging Member of the LLC.Oct 2013
James O'BrienJames O'Brien is a Managing Member of the LLC.Dec 2011